Paclitaxel and its formulations

International Journal of Pharmaceutics

Volumn 235, Issue 1-2, 2002, Pages 179-192

  Singla, Anil K ^a   Garg, Alka ^a   Aggarwal, Deepika ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Formulation; Paclitaxel; Solubility; Taxol

Indexed keywords

ANTINEOPLASTIC AGENT; CREMOPHOR; CYCLODEXTRIN DERIVATIVE; DRUG SOLVENT; DRUG VEHICLE; PACLITAXEL;

ALLERGIC REACTION; AQUEOUS SOLUTION; ARTICLE; BREAST CARCINOMA; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG TOLERANCE; EMULSION; HUMAN; MICELLE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; PACLITAXEL;

EID: 0037139411     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(01)00986-3     Document Type: Article

References (103)

1. Taxol: A history of pharmaceutical development and current pharmaceutical concerns
2. The extraction of diethylhexylpthalate (DEHP) from polyvinylchloride components of intravenous infusion containers and administration sets by paclitaxel injection
3. Management of breast cancer
4. Taxol® (paclitaxel): Historical and ecological aspects
5. Taxus brevifolia: Clinical gem or endangered species?
6. Experimental antitumor activity of taxotere (RP56976, NSC628503) a taxol analogue
7. Liquids
8. A phase-I trial of taxol given by 6-hour infusion
9. Controlled delivery of taxol from microspheres composed of a blend of ethylene vinyl acetate copolymer
10. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water soluble prodrugs of paclitaxel
11. Taxol metabolism by human liver microsomes: Identification of cytochrome P-450 isozymes involved in its biotransformation
12. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes
13. Interaction of taxol and other anticancer drugs with alpha-cyclodextrin
14. Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activity
15. Solubility and stability of taxol: Effects of buffers and cyclodextrins
16. Release of taxol from poly(e-caprolactone)pastes: Effect of water-soluble additives
17. Pharmacology and toxicology of Cremophor EL diluent
18. Preparation, characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugate
19. Suspected anaphylactic reaction to Cremophor EL
20. A non-surfactant formulation of alfaxalone based on an amorphous cyclodextrin. Activity studies in rats and dogs
21. Solubility concepts and their apllication to the formulation of pharmaceutical systems
22. Hypersenstivity reactions from taxol and etoposide
23. Highly water soluble taxol derivatives: 2′-polyethylene glycol esters as potential prodrugs
24. Water soluble taxol 2′-poly (ethylene glycol) ester prodrugs-design and in vivo effectiveness
25. Interactions of taxol, microtubule associated proteins, and guanine nucleotide in tubulin polymerization
26. Phase II trials of taxol, an active drug in the treatment of metastatic breast cancer
27. First total synthesis of taxol
28. Mechanism of action of Taxol
29. Anaphylactoid reactions asociated with parenteral cyclosporine use: Possible role of Cremophor EL
30. Metabolism of taxol by human liver microsomes and effect of inhibitors
31. Development of nonionic surfactant/phospholipid O/W emulsion as a paclitaxel delivery system
32. Block copolymer micelles as vehicle for drug delivery
33. Effect of cimetidine, probenecid and ketoconazole on the distribution, billiary secretion and metabolism of 3H-taxol in the Sprague-Dawley rat
34. Interaction of Cremophor EL with human plasma
35. Local chemotherapy with slowly-releasing anticancer drug-polymers for malignant brain tumors
36. Binding of taxol to human plasma, albumin and acid glycoprotein
37. Pharmacokinetics and pharmacodynamics of the taxanes
38. The influence of Cremophor EL on the cell cycle of paclitaxel (Taxol®) in the human cell lines
39. What you need to know about taxol?
40. High performance liquid chrometographic assay for taxol in human plasma and urine and pharmacokinetics in phase I trials
41. Histamine release in dogs by Cremophor EL and its derivatives: Oxyethylated oleic acid is the most effective constituent
42. A submicron lipid emulsion coated with amphipathic polyethylene glycol for parentral administration of paclitaxel (taxol)
43. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms
44. Preparation and biological activity of taxol acetates
45. Development of novel chitosan derivatives as micellar carriers of taxol
46. Sterlization of substances in circulation
47. Taxol metabolism. Isolation and identification of three major metabolites of taxol in rat bile
48. Design, synthesis and biological activity of protaxols
49. Total synthesis of taxol
50. The cytotoxic activity of taxol in primary cultures of tumor cells from patients is partly mediated by Cremophor EL
51. Hypersenstivity reactions to teniposide (VM26): On analysis
52. Taxol: Finite supply and increasing demand
53. A mixed micellar formulation suitable for the parenteral administration of taxol
54. Biodegradable polyanhydride devices of cefazolin sodium, bupivacaine, and taxol for local drug delivery: Preparation, and kinetics and mechanism of in vitro release
55. Taxol binds to polymerized tubulin in vitro
56. Precipitation of paclitaxel during infusion by pump
57. 2-antagonist drug interactions: Concept and implications
58. Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers
59. Analysis of anticancer drug in biological fluids: Determination of taxol with application to clinical pharmacokinetics
60. Paclitaxel (Taxol®)
61. The clinical pharmacology of paclitaxel (Taxol®)
62. Clinical toxicities encountered with paclitaxel (Taxol®)
63. Taxol: The first of the taxanes,an important new class of antitumor agents
64. Taxol: A novel investigational antimicrotubule agent
65. Liposomes as carriers of different new lipophilic antitumor drugs: A preliminary report
66. Promotion of microtubule assembly in vitro by taxol
67. Taxol stabilize microtubules in mouse fibroblast cells
68. Antitumor effects of taxol-containing liposomes in a taxol resistant murine tumor model
69. Novel Taxo formulations: Preparation and characterization of Taxol-containing liposomes
70. Pharmaceutical and physical properties of paclitaxel (taxol) complexes with cyclodextrins
71. Emulsion formulation for intravenous administration of paclitaxel
72. Effect of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymer
73. Binding of taxol to plastic glass containers and protein under in vitro conditions
74. Paclitaxel
75. Biopharmaceutics of paclitaxel (taxol): Formulation, activity, and pharmacokinetics
76. Biologically active taxol analogues with deleted A-ring side chain substituent and variable
77. Effects of Cremophor EL on distribution of taxol to serum lipoproteins
78. Cyclodextrins in drug formulations
79. Cyclodextrins in drug formulations
80. A new parenteral vehicle for the administration of some poorly soluble anti-cancer drugs
81. Turbidimetric assesment of the compatibility of taxol with selected other drugs during simulated Y-site injection
82. Turbidimetric assesment of the compatibility of taxol with 42 other drugs during simulated Y-site injection
83. Improvement of dissolution and absorption characteristics of benzodiazepines by cyclodextrin complexation
84. Cyclodextrins in drug carrier systems
85. Leaching of diethylhexaphathalate from polyvinylchloride bags into intravenous cyclosporin solution
86. Comptothecin and taxol: From discovery to clinic
87. Interstitial taxol delivered from biodegradable polymer implant against experimental malignant glioma
88. Towards the total synthesis of taxol and its analogues
89. Preparation and characterization of poly(lactic-co-glycolic acid) microspheres for targeted delivery of novel anticancer agent, taxol
90. Plant antitumor agents: VI The isolation and structure of taxol, a novel anti leukemic and antitumor agent from Taxus brevifolia
91. Stability, compatibility, and plasticizer extraction of taxol (NSC125973) injection diluted in infusion solutions and stored in various containers
92. Hypersenstivity reactions with taxol
93. Polyethylene glycol modified phosoholipids stabilize emulsions prepared from triacylglycerol
94. Phase I trials of taxol given as 24-hour infusion every 21 days: Responses observed in metastatic melanoma
95. Phase I clinical and pharmacokinetic study of taxol
96. Development of polymeric surgical paste formulation for taxol
97. Taxus species needles containing amounts of taxol comparable to the bark of Taxus brevifolia
98. In vivo versus in vitro degradation of controlled release polymers for intracranial surgical therapy
99. Paclitaxel compatibility with the IV Express filter unit
100. Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin conjugated poly (ethyleneglycol)-poly (aspartic acid) block copolymer